Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Maintaining Abstinence in Chronic Cigarette Smokers - 1

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2008 by National Institute on Drug Abuse (NIDA).
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00087880
First received: July 15, 2004
Last updated: November 13, 2008
Last verified: November 2008

July 15, 2004
November 13, 2008
December 2002
January 2005   (final data collection date for primary outcome measure)
Smoking Behavior [ Time Frame: 2 ] [ Designated as safety issue: No ]
Smoking Behavior
Complete list of historical versions of study NCT00087880 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Maintaining Abstinence in Chronic Cigarette Smokers - 1
Maintaining Abstinence in Chronic Cigarette Smokers

The purpose of this study is to evaluate the extended pharmacological and psychological treatment for chronic cigarette smokers.

The work adapts interventions that have been successful in the general populations, and tailors them to chronic smokers, who may have numerous previous smoking treatment failures. If successful it will: (1) make available a treatment intervention that produces hight long term abstinence rates; (2) provide information on variables that predicts success and failure in this population of smokers; (3) examine the cost-effectiveness of more intensive, longer term treatments.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Tobacco Use Disorder
Drug: Bupropion and NRT
All participants receive standard 12 week treatment of NRT, bupropion and five group counseling sessions. At week 11, subjects are randomly assigned to one of five treatment groups (1) Bupropion/Low Contact; (2) Placebo/Low Contact; (3) Bupropion/Relapse Prevention; (4) Placebo/Relapse Prevention; (5) No Further Treatment. Data is collected at Week 0, and at weeks 12, 24, 52, 64, and 104.
Other Name: Zyban
  • Active Comparator: Brief Treatment
    Participants will start with a 21 mg nicotine patch, tapering to 14 mg patch and finally tapering to 7 mg patch. The nicotine patch will be administered on Week 3 of the program. Participants will meet with medical staff during Weeks 1, 2, 5, and 11. Five group counseling sessions must be attended by the participants. Assessments will be conducted on Weeks 12, 24, 36, 52, 64, and 104.
    Intervention: Drug: Bupropion and NRT
  • Active Comparator: Extended Bupropion/Low Contact
    Participants will receive the Brief Treatment followed by ongoing Bupropion treatment through Week 52. Participants will meet with medical staff once a month.
    Intervention: Drug: Bupropion and NRT
  • Placebo Comparator: Extended Placebo/Low Contact
    Participants will receive the Brief Treatment followed by placebo medication (sugar-pill) through Week 52 and meet with medical staff once a month.
    Intervention: Drug: Bupropion and NRT
  • Active Comparator: Extended Bupropion/High Contact
    Participants will receive Brief Treatment followed by ongoing bupropion treatment through Week 52. Participants will attending counseling session 20-40 minutes in duration and will be scheduled at weeks 12, 14, 16, 18, 20, 24, 28, 32, 36, 44, and 52. The contents of these sessions will introduce additional information focusing on motivation, social support, mood management, weight gain, and dependence/withdrawal. Subjects will be contact by phone between counseling sessions (at Weeks 13, 15, 18, 22, 26, 30, 34, 36, 40, 48) for a brief check-in.
    Intervention: Drug: Bupropion and NRT
  • Placebo Comparator: Extended Placebo/High Contact
    Participants receive the Brief Treatment followed by a placebo medication through Week 52 and meet with medical staff once per month. Participants will attending counseling session 20-40 minutes in duration and will be scheduled at weeks 12, 14, 16, 18, 20, 24, 28, 32, 36, 44, and 52. The contents of these sessions will introduce additional information focusing on motivation, social support, mood management, weight gain, and dependence/withdrawal. Subjects will be contact by phone between counseling sessions (at Weeks 13, 15, 18, 22, 26, 30, 34, 36, 40, 48) for a brief check-in.
    Intervention: Drug: Bupropion and NRT
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
407
September 2009
January 2005   (final data collection date for primary outcome measure)

Subjects (N=400) will be men and women (50%) over the age of 18 who smoke at least 10 cigarettes per day and answers yes to the question "Do you smoke within 30 minutes of arising?"

Inclusion Criteria:

-Subjects are age 18 and over, currently smoking 10 or more cigarettes per day, and report a smoking history of at least 5 years in response to the question "How long have you been a regular smoker?"

Exclusion Criteria:

  • History of seizure or head injury resulting in unconsciousness
  • Any condition that might predispose to seizures (brain tumor or stroke)
  • A current or history of anorexia nervosa or bulimia
  • Any disease acutely life-threatening or so severe that the patient is judged unable to comply with the protocol
  • Use of a protease inhibitor of MAO inhibitor within the last two week
  • Current use of psychiatric drugs that would interfere with interpretation of study results, including antidepressants
  • Treatment for alcohol dependence during the last year, or evidence of alcohol abuse so severe that the patient is judged potentially unable to comply with the protocol
  • Patients who know they are leaving the Bay Area within the study period and non-English speakers will be excluded
  • Suicidal or homicidal ideation
  • Current major depression
  • History of bipolar disorder
  • Recent (within twelve months) myocardial infarction
  • Any other medical condition that would contraindicate use of NRT or bupropion
  • Physical limitation so severe that participation in a program of moderate exercise is not possible
  • Pregnancy or lactation
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00087880
NIDA-15732-1, R01-15732-1
No
Sharon M. Hall, Ph.D, University California, San Francisco
National Institute on Drug Abuse (NIDA)
Not Provided
Principal Investigator: Sharon M Hall, Ph.D. University of California, San Francisco
National Institute on Drug Abuse (NIDA)
November 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP